Progyny (NASDAQ:PGNY) Research Coverage Started at Barclays

Barclays initiated coverage on shares of Progyny (NASDAQ:PGNY) in a research note published on Monday, Marketbeat reports. The brokerage issued an overweight rating and a $29.00 price objective on the stock.

PGNY has been the topic of a number of other reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Progyny in a research note on Wednesday, October 8th. Canaccord Genuity Group increased their target price on Progyny from $23.00 to $26.00 and gave the company a “hold” rating in a research report on Monday, November 17th. KeyCorp upgraded Progyny from a “sector weight” rating to an “overweight” rating and set a $30.00 price target on the stock in a report on Tuesday, November 11th. Finally, JPMorgan Chase & Co. upped their price objective on Progyny from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Progyny presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.50.

Progyny Stock Up 1.8%

PGNY stock opened at $25.17 on Monday. The business’s fifty day simple moving average is $22.25 and its two-hundred day simple moving average is $22.31. The firm has a market cap of $2.17 billion, a price-to-earnings ratio of 39.95, a PEG ratio of 1.95 and a beta of 0.97. Progyny has a twelve month low of $13.86 and a twelve month high of $27.51.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, November 6th. The company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.06. The business had revenue of $313.35 million for the quarter, compared to the consensus estimate of $299.23 million. Progyny had a net margin of 4.46% and a return on equity of 10.71%. The company’s revenue for the quarter was up 9.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.11 EPS. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS and its Q4 2025 guidance at 0.370-0.400 EPS. Research analysts expect that Progyny will post 0.6 EPS for the current year.

Insider Activity

In other Progyny news, CFO Mark S. Livingston sold 21,303 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $25.50, for a total transaction of $543,226.50. Following the completion of the transaction, the chief financial officer directly owned 48,358 shares of the company’s stock, valued at approximately $1,233,129. This trade represents a 30.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Peter Anevski acquired 79,500 shares of the firm’s stock in a transaction on Thursday, November 13th. The shares were acquired at an average price of $24.29 per share, with a total value of $1,931,055.00. Following the completion of the purchase, the chief executive officer owned 680,251 shares in the company, valued at approximately $16,523,296.79. This trade represents a 13.23% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders sold 22,046 shares of company stock valued at $561,691. Company insiders own 9.40% of the company’s stock.

Institutional Trading of Progyny

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. California State Teachers Retirement System raised its holdings in Progyny by 0.7% in the 2nd quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock worth $1,549,000 after purchasing an additional 457 shares during the period. Leibman Financial Services Inc. increased its position in shares of Progyny by 1.1% in the second quarter. Leibman Financial Services Inc. now owns 45,946 shares of the company’s stock valued at $1,011,000 after buying an additional 513 shares in the last quarter. Teza Capital Management LLC increased its position in shares of Progyny by 5.4% in the second quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock valued at $221,000 after buying an additional 516 shares in the last quarter. Aristides Capital LLC raised its stake in shares of Progyny by 4.6% during the 3rd quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock worth $257,000 after buying an additional 528 shares during the period. Finally, Oxford Asset Management LLP lifted its position in shares of Progyny by 4.3% during the 2nd quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock valued at $284,000 after buying an additional 531 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.